Previous 10 | Next 10 |
home / stock / ipsey / ipsey news
Ipsen’s Rare Diseases portfolio significantly enhanced with late-stage drug candidate, palovarotene, for the treatment of rare bone disorders in adult and pediatric patients Transaction reinforces Ipsen’s strong commitment to providing life-altering treatments to patie...
Allergan ( AGN ) originally received FDA approval for Botox type A in 2002, derived from botulinum toxin, made by the bacteria that causes botulism (clostridium botulinum). Many are familiar with the cosmetic uses of Botox (onabotulinum toxin A), but not so many are familiar with the medical u...
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) announced today that its 2018 Registration Document has been filed with the French “ Autorité des Marchés Financiers ” (AMF) on 26 March 2019 and registered under the number D.19-0205. The document is ava...
Aleafia (ALEAF) - Emblem ( EMMBF ) All Stock Merger Spread: 8%. Closing: a few weeks. Merger consideration: 0.8377 ALEF This is a micro cap deal in the Canadian cannabis industry. Despite that, recently there has been a high number of M&A deals in this industry, most of them were s...
Studies Demonstrate Ipsen’s Ongoing Commitment to Innovation and Improving Patient Care in Neuroendocrine Tumors (NETs) Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced that they are looking forward to revealing 17 presentations that detail their researc...
Like a lot of players in the healthcare industry, it's a popular move to grow your offerings by acquiring other companies, and there have been thousands of such acquisition over the past few decades. Clementia Pharmaceuticals' ( CMTA ) primary drug development is called Palovarotene , which...
Ipsen ( OTCPK:IPSEY ) has agreed to acquire Clementia Pharmaceuticals (NASDAQ: CMTA ) for $25 per share in cash plus a contingent value right (CVR) of $6 per share ($263M) related to the FDA acceptance of a marketing application seeking approval for lead drug palovarotene for the treatment...
Seeking to keep pace in gene therapy with rivals like Novartis (NYSE: NVS ), Roche ( OTCQX:RHHBY ) is buying Spark Therapeutics (NASDAQ: ONCE ) for $114.50 per share, or $4.3B, a premium of about 122% to Spark's closing price on Feb. 22. More news on: Novartis AG, Roche Holding Ltd ADR, ...
Clementia’s late-stage drug candidate, palovarotene, has rare pediatric disease and breakthrough therapy designations for the treatment of an ultra-rare bone disorder and a path to approval in 2020 Acquisition to transform Ipsen’s Rare Disease portfolio by leveraging C...
Ipsen S.A. ADR (IPSEY) Q4 2018 Results Earnings Conference Call February 14, 2019, 08:30 AM ET Company Participants David Meek - CEO Aymeric Chatelier - Executive VP & CFO Conference Call Participants Richard Vosser - JPMorgan Presentation Operator David Meek ...
News, Short Squeeze, Breakout and More Instantly...
Ipsen SA ADR Company Name:
IPSEY Stock Symbol:
OTCMKTS Market:
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases Canada NewsWire Ipsen enters into an option agreement to receive exclusive global rights to two candidates pursued under the collaboration Following development ...
Marengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen PR Newswire A Novel TCR Vβ bifunctional selective T cell activator molecule for solid tumor treatment Marengo to receive an associated milestone payment a...
Turnstone Biologics Corp. (TSBX) is expected to report $-0.73 for Q4 2023 Exro Technologies Inc (EXROF) is expected to report for Q4 2023 Boyd Gaming Corporation (BYD) is expected to report $1.43 for Q4 2023 Onto Innovation Inc. (ONTO) is expected to report $0.99 for Q4 2023 Motor...